SCHEMBL14636776

SCHEMBL14636776

O=C(Nc1ccccn1)c1ccc(Br)nc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 10/20 0.71
RAB9A P51151 10/20 0.71
MEN1 O00255 4/20 0.61
KMT2A Q03164 4/20 0.61
F2 P00734 1/20 0.57
GRM5 P41594 1/20 0.57
MITF O75030 1/20 0.54
SMN1; SMN2 Q16637 6/20 0.53
PKM P14618 3/20 0.53
ALOX15 P16050 1/20 0.52
NPSR1 Q6W5P4 2/20 0.52
LMNA P02545 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 1/20 0.51
HCAR3 P49019 1/20 0.51
TP53 P04637 2/20 0.51
GAA P10253 1/20 0.51
CHRNB2 P17787 1/20 0.51
CHRNB4 P30926 1/20 0.51
CHRNA3 P32297 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16594642 0.83 RAB9A (0.83) NPC1RAB9AMEN1KMT2AF2
SCHEMBL3788722 0.82 SMN1; SMN2 (0.74) NPC1RAB9AMEN1KMT2AF2
SCHEMBL3499621 0.82 CHRNB2 (0.59) NPC1RAB9AMEN1KMT2AGRM5
SCHEMBL2815369 0.82 NPC1 (0.71) NPC1RAB9AMEN1KMT2AF2
SCHEMBL17928433 0.81 HCAR3 (0.57) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL3500869 0.80 NPC1 (0.66) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL3502440 0.80 NPC1 (0.66) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL3500140 0.80 HCAR3 (0.69) NPC1RAB9AMEN1KMT2AHCAR3
SCHEMBL29366822 0.79 RAB9A (0.89) NPC1RAB9AMEN1KMT2AF2
SCHEMBL997866 0.79 RAB9A (0.89) NPC1RAB9AMEN1KMT2AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2734529-B1 BTK INHIBITORS MERCK SHARP & DOHME (US) 2018-09-05 EP disclosed
US-9718828-B2 BTK Inhibitors MERCK SHARP & DOHME CORP. (US) 2017-08-01 US disclosed
US-20170008899-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20140221333-A1 BTK INHIBITORS MERCK SHARP & DOHME B.V. (NL) 2014-08-07 US disclosed
EP-2734529-A1 BTK INHIBITORS Merck Sharp & Dohme Corp. (US) 2014-05-28 EP disclosed
WO-2013010380-A1 BTK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008899-A1 BTK INHIBITORS BTK, SYK, ABL1 NPC1 3286/4885RAB9A 1303/4885MEN1 3179/4885
US-20140221333-A1 BTK INHIBITORS BTK, SYK, ABL1 NPC1 3341/4885RAB9A 1294/4885MEN1 2995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.